Denali expects $30M-$32M Q4 AVLAYAH net product revenue as Sanfilippo BLA filing remains planned for 2027

2 articles from 1 source · updated November 4, 2026, 02:50 UTC

Coverage

Denali expects $30M-$32M Q4 AVLAYAH net product revenue as Sanfilippo BLA filing remains planned for 2027 Seeking Alpha · November 4, 2026, 02:46 UTC
Denali Therapeutics Projects $30M-$32M Q4 Revenue for AVLAYAH Amid Hunter Syndrome Commercialization Seeking Alpha · November 4, 2026, 02:46 UTC